Samil Pharmaceutical삼일제약

Samil Pharmaceutical remains loss-making on trailing results, with heavy borrowings and a share price well below its 52-week high.

Trailing twelve-month revenue is about ₩207B, but operating loss is about ₩28B and net loss about ₩38B as of H1 2026, with liabilities at 198.5% of equity. The share price closed at ₩7,640 on 27 October 2026, down 21.5% over one year but up 22.6% over three months, and no dividend is paid. The data does not include a fair value estimate or analyst views.

What stands out

• Revenue fell 4.3% in 2025 to about ₩210B after rising 11.9% in 2024, and operating margin turned negative at -10.6% in 2025 after a near-breakeven 2024.
• Borrowings of about ₩174B are far above cash of about ₩6.1B, and free cash flow over the trailing period was negative at about -₩2.2B.
• Valuation shows a price-to-book of 1.3 and price-to-sales of 0.8, but no P/E because earnings are negative; the dividend yield is 0%.
• Foreign ownership fell from 4.0% to 3.3% over 60 days, while the 20-day investor flows show foreign net selling of about ₩108M.
• Recent filings are mainly insider shareholding reports, 5%+ holding reports, a convertible bond issue decision in June 2026 and the half-year report; no news headlines were provided.

What to watch

• The next periodic results and whether losses narrow from the H1 2026 trailing figures.
• Debt levels and refinancing, given borrowings well above cash and a liabilities-to-equity ratio near 200%.
• Further 5%+ holding and insider shareholding filings, and the outcome of the convertible bond issued in June 2026.